Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Harrison

Showing results (51-60 of 583) with videos related to

Pageof 59
Sort By:
Hematology/Oncology Clinics of North America|October 17, 2003
Essential thrombocythemiaClaire N Harrison, Anthony R Green
Thorax|June 1, 1979
Acute actinomycotic empyemaR N Harrison, D J Thomas
The Journal of Trauma|October 1, 1972
The effect of cleansing agents used on the burn wound (Betadine, Joy), hydrotherapy, and the presence of residual cream on the absorption of sulfamylon into the burn woundK H Burns, H N Harrison
Best Practice & Research. Clinical Haematology|June 20, 2006
Essential thrombocythaemiaClaire N Harrison, Anthony R Green
Clinical Advances in Hematology & Oncology : H&O|May 10, 2018
Myelofibrosis: clinicopathologic features, prognosis, and managementJennifer M O'Sullivan, Claire N Harrison
British Journal of Haematology|March 14, 2020
Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasmsDonal P McLornan, Claire N Harrison
Blood|January 23, 2016
Closing the gap: genetic landscape of MPNClaire N Harrison, Alessandro M Vannucchi
Blood Advances|February 20, 2020
Guidance on changing therapy choice in myelofibrosisDonal P McLornan, Claire N Harrison
Public Health|August 9, 2005
Factors affecting the uptake of cardiac rehabilitation services in a rural localityW N Harrison, S A Wardle
Future Oncology (London, England)|October 24, 2017
An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasmsNatalia Curto-Garcia, Claire N Harrison
Pageof 59

Showing results (51-60 of 583) with videos related to

Sort By:
Pageof 59
Hematology/Oncology Clinics of North America|October 17, 2003
Essential thrombocythemiaClaire N Harrison, Anthony R Green
Thorax|June 1, 1979
Acute actinomycotic empyemaR N Harrison, D J Thomas
The Journal of Trauma|October 1, 1972
The effect of cleansing agents used on the burn wound (Betadine, Joy), hydrotherapy, and the presence of residual cream on the absorption of sulfamylon into the burn woundK H Burns, H N Harrison
Best Practice & Research. Clinical Haematology|June 20, 2006
Essential thrombocythaemiaClaire N Harrison, Anthony R Green
Clinical Advances in Hematology & Oncology : H&O|May 10, 2018
Myelofibrosis: clinicopathologic features, prognosis, and managementJennifer M O'Sullivan, Claire N Harrison
British Journal of Haematology|March 14, 2020
Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasmsDonal P McLornan, Claire N Harrison
Blood|January 23, 2016
Closing the gap: genetic landscape of MPNClaire N Harrison, Alessandro M Vannucchi
Blood Advances|February 20, 2020
Guidance on changing therapy choice in myelofibrosisDonal P McLornan, Claire N Harrison
Public Health|August 9, 2005
Factors affecting the uptake of cardiac rehabilitation services in a rural localityW N Harrison, S A Wardle
Future Oncology (London, England)|October 24, 2017
An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasmsNatalia Curto-Garcia, Claire N Harrison
Pageof 59